EUVIMEDEUVIMED entdecken
Crossref

Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs

Scott P Henry, Cecilia Arfvidsson, Josh Arrington, Jasna Canadi, Dave Crowe iD, Shalini Gupta, Sabine Lohmann, Benoit Massonnet, Daniel Mytych, Tina Rogers, Hobart Rogers, Chris Stebbins und 7 weitere

Nucleic Acid Therapeutics · 01.10.2022 · 32 (5) · 369-377

DOI: 10.1089/nat.2021.0112 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 14.10.2022. Verfasst von Scott P Henry und 18 weiteren Autor:innen. Beteiligte Einrichtung: Ionis Pharmaceuticals, Inc., Carlsbad, California, USA. Hauptthemen laut MEDLINE: Oligonucleotides, Biological Products. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Therapeutic oligonucleotides (ONs) have characteristics of both small molecules and biologics. Although safety assessment of ONs largely follows guidelines established for small molecules, the unique characteristics of ONs often require incorporation of concepts from the safety assessment of biologics. The assessment of immunogenicity for ON therapeutics is one area where the approach is distinct from either established small molecule or biologic platforms. Information regarding immunogenicity of ONs is limited, but indicates that administration of ONs can result in antidrug antibody formation. In this study, we summarize the collective experience of the Oligonucleotide Safety Working Group in designing the immunogenicity assessment appropriate for this class of therapeutic, including advice on assay development, clinical monitoring, and evaluation of the impact of immunogenicity on exposure, efficacy, and safety of therapeutic ONs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OligonucleotidesBiological ProductsPharmaceutical PreparationsAntibodies

Stichwörter der Autor:innen

antidrug antibodiesimmunogenicity testingoligonucleotides

Substanzen

OligonucleotidesPharmaceutical PreparationsAntibodiesBiological Products

Autor:innen und Institutionen

  • Ionis Pharmaceuticals, Inc., Carlsbad, California, USA.
  • Clinical Pharmacology & Safety Sciences, Astra Zeneca, Mölndal, Sweden.
  • Arrowhead Pharmaceuticals, Pasadena, California, USA.
  • F. Hoffmann-La Roche Ltd., Basel, Switzerland.
  • Disc Medicine, Cambridge, Massachusetts, USA.
  • Amgen, Thousand Oaks, California, USA.

ORCID-Profile: Dave Crowe, Adam Vigil

Zitieren

APA

Henry, S. P., Arfvidsson, C., Arrington, J., Canadi, J., Crowe, D., Gupta, S., Lohmann, S., Massonnet, B., Mytych, D., Rogers, T., Rogers, H., Stebbins, C., Stovold, C., Verthelyi, D., Vigil, A., Xuan, C., Xu, Y., Yu, R., & Klem, T. (2022). Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs. Nucleic Acid Therapeutics, 32(5), 369-377. https://doi.org/10.1089/nat.2021.0112

Vancouver

Henry SP, Arfvidsson C, Arrington J, Canadi J, Crowe D, Gupta S, et al. Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs. Nucleic Acid Therapeutics. 2022;32(5):369-377. doi:10.1089/nat.2021.0112

BibTeX
@article{Henry2022,
  author = {Henry, Scott P and Arfvidsson, Cecilia and Arrington, Josh and Canadi, Jasna and Crowe, Dave and Gupta, Shalini and Lohmann, Sabine and Massonnet, Benoit and Mytych, Daniel and Rogers, Tina and Rogers, Hobart and Stebbins, Chris and Stovold, Craig and Verthelyi, Daniela and Vigil, Adam and Xuan, Chi and Xu, Yuanxin and Yu, Rosie and Klem, Thomas},
  title = {Assessment of the Immunogenicity Potential for Oligonucleotide-Based Drugs},
  journal = {Nucleic Acid Therapeutics},
  year = {2022},
  volume = {32},
  number = {5},
  pages = {369--377},
  doi = {10.1089/nat.2021.0112}
}
Kostenlos starten →